No effect from Argentina export tax, page-63

First 63 Last

Share
Profile

Follow
Ninja Tuna

2,853 Posts.

996

17/09/18

10:24

Post #: 35640350
Share

Originally posted by ProCapitalism ↑

There have been posts on the GXY threads detailing concerns about the economic conditions in Argentina & the risks associated with the development of SDV.

Below is a daily chart of the US index & something I've noticed is there appears to be a head & shoulders top forming. For conformation the $94.23 neckline needs to be broken before a bearish move down in the USD begins.

View attachment 1294157

I bring this up for 2 reasons.

1. Does anyone know if GXY will hold the entire amount of the $280 million payment they get from Posco in USD?

If the payment occurs in the coming months before the potential reversal in the USD begins perhaps it would be wise for GXY management to convert some of this payment straight to AUD or another currency like the Canadian dollar (for JB development)? Splitting the payment up into several currencies in the countries GXY plans to develop mines will serve as a hedge towards a falling USD.

2. But the main reason I bring up the USD & the chart is to point out developing economies like Argentina & others around the world generally do better when the USD is falling, therefor economic conditions may begin to improve in Argentina over the coming months/years if the decline in the USD is sustained. This inturn will de-risk our SDV development significantly IMO.

On the other hand if the USD continues to rise all GXY has to do is make payments for the Argentinean SDV development in USD.

It's a win-win move for GXY as far as I'm concerned.

SDV needs to start ramping up & the sooner the better.

Just some thoughts I had on a lazy Sunday. Let's hope the trading week for GXY gets better on Monday.

Expand

Yes payment in USD I expect.
GXY also switched financial reporting denomination to USD for the same reasons you mentioned.
1. Easier comparison to the majors as we are now considered a major
2. Easier to pay and receive everything in USD so as to minimise spot/forward risk in USD ARS and AUD USD.

Just my opinion of course
Cheers

GXY Price at posting: $2.50 Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BUX

Buxton projects new graphite province discovery at WA Narryer play

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 1 more message in this thread...

First 63 Last

Add GXY (ASX) to my watchlist

No effect from Argentina export tax, page-63

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Buxton projects new graphite province discovery at WA Narryer play

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News